SAN FRANCISCO — Attorneys from Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised on genomics technology firm Fluidigm Corp.’s $208 million acquisition of DVS Sciences Inc., which makes a device used to analyze single cells in biological research.
The deal between the Bay Area companies is geared toward enhancing Fluidigm’s offerings at the single-cell level. Bringing together technologies pioneered by the two companies could “transform single-cell analysis for life sciences research, drug development, and potentially diagnostics,” said Dr. Scott Tanner, chief technology officer and co-founder of DVS.
